# Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

> **NCT02581410** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 430 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

## Key facts

- **NCT ID:** NCT02581410
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-15
- **Primary completion:** 2016-08-30
- **Final completion:** 2017-08-01
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581410, "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02581410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*